dr. rini describes axitinib's and sorafenib's side effects
Published 13 years ago • 1.1K plays • Length 1:12Download video MP4
Download video MP3
Similar videos
-
0:38
dr. rini explains the axitinib integration process
-
0:43
dr. rini on the results from his axitinib and sorafenib trial
-
0:43
dr. rini discusses the vegf targeted agent axitinib
-
0:44
dr. rini on the axitinib and sorafenib trial vegf focus
-
2:16
dr. rini on axitinib for treatment of metastatic renal cell carcinoma
-
5:10
real-world treatment outcomes of 1l axitinib pembrolizumab in patients with advanced rcc in the us
-
1:00:38
medullary thyroid cancer & new therapies with dr. elisei
-
15:17
prof ricardi’s and dr sugie’s testimonial on the radixact system with synchrony
-
2:16
axitinib showed two-month advantage to sorafenib
-
0:53
dr. rini on standards of care for advanced rcc
-
1:34
dr. rini on pembrolizumab plus axitinib in rcc
-
1:19
dr. rini on the efficacy of axitinib and pembrolizumab in rcc
-
2:11
dr. cella discusses axitinib and sorafenib axis trial
-
9:05
drs. rini, wallis on a 5-year analysis of keynote-426 for advanced clear cell rcc
-
1:03
dr. rini on managing the toxicity of pembrolizumab plus axitinib in mrcc
-
6:59
single-agent axitinib therapy in patients with unresectable recurrent cancer - paul swiecicki
-
9:52
phase 3 axitinib data in patients with previously treated advanced renal cell carcinoma
-
4:38
esmo 2023: renotorch assesses toripalimab and axitinib in rcc
-
0:45
dr. rini on the progression of advanced rcc therapy
-
1:04
dr. rini discusses pembrolizumab plus axitinib in mrcc
-
2:20
the multi-receptor inhibitor axitinib reverses tumor-induced immunosuppression and potentiates treat
-
1:19
dr. nicholas vogelzang on first-line axitinib versus sorafenib in mrcc